JP2020510045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510045A5 JP2020510045A5 JP2019549459A JP2019549459A JP2020510045A5 JP 2020510045 A5 JP2020510045 A5 JP 2020510045A5 JP 2019549459 A JP2019549459 A JP 2019549459A JP 2019549459 A JP2019549459 A JP 2019549459A JP 2020510045 A5 JP2020510045 A5 JP 2020510045A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- treatment
- disease
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 claims 9
- 229950009275 ponesimod Drugs 0.000 claims 9
- 239000004480 active ingredient Substances 0.000 claims 8
- 229960000681 leflunomide Drugs 0.000 claims 8
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 229960000331 teriflunomide Drugs 0.000 claims 8
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 230000003044 adaptive effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022204487A JP2023030091A (ja) | 2017-03-14 | 2022-12-21 | ポネシモドを含有する医薬的組み合わせ |
| JP2024067486A JP2024096962A (ja) | 2017-03-14 | 2024-04-18 | ポネシモドを含有する医薬的組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2017/055994 | 2017-03-14 | ||
| EP2017055994 | 2017-03-14 | ||
| PCT/EP2018/056185 WO2018167030A1 (en) | 2017-03-14 | 2018-03-13 | Pharmaceutical combination comprising ponesimod |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022204487A Division JP2023030091A (ja) | 2017-03-14 | 2022-12-21 | ポネシモドを含有する医薬的組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510045A JP2020510045A (ja) | 2020-04-02 |
| JP2020510045A5 true JP2020510045A5 (enExample) | 2021-04-22 |
| JP7281406B2 JP7281406B2 (ja) | 2023-05-25 |
Family
ID=61655772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549459A Active JP7281406B2 (ja) | 2017-03-14 | 2018-03-13 | ポネシモドを含有する医薬的組み合わせ |
| JP2022204487A Pending JP2023030091A (ja) | 2017-03-14 | 2022-12-21 | ポネシモドを含有する医薬的組み合わせ |
| JP2024067486A Pending JP2024096962A (ja) | 2017-03-14 | 2024-04-18 | ポネシモドを含有する医薬的組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022204487A Pending JP2023030091A (ja) | 2017-03-14 | 2022-12-21 | ポネシモドを含有する医薬的組み合わせ |
| JP2024067486A Pending JP2024096962A (ja) | 2017-03-14 | 2024-04-18 | ポネシモドを含有する医薬的組み合わせ |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11723896B2 (enExample) |
| EP (1) | EP3595657A1 (enExample) |
| JP (3) | JP7281406B2 (enExample) |
| KR (1) | KR102574562B1 (enExample) |
| CN (1) | CN110381942B (enExample) |
| AU (2) | AU2018233109B2 (enExample) |
| BR (1) | BR112019018894A2 (enExample) |
| CA (1) | CA3056301C (enExample) |
| CL (1) | CL2019002525A1 (enExample) |
| CO (1) | CO2019008510A2 (enExample) |
| CR (1) | CR20190464A (enExample) |
| DO (1) | DOP2019000257A (enExample) |
| EA (1) | EA201992117A1 (enExample) |
| EC (1) | ECSP19073317A (enExample) |
| IL (1) | IL269239B2 (enExample) |
| JO (1) | JOP20190207A1 (enExample) |
| MA (1) | MA49822A (enExample) |
| MX (1) | MX390941B (enExample) |
| NI (1) | NI201900092A (enExample) |
| PE (1) | PE20191489A1 (enExample) |
| PH (1) | PH12019502110A1 (enExample) |
| SG (1) | SG11201907308UA (enExample) |
| UA (1) | UA125756C2 (enExample) |
| WO (1) | WO2018167030A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| EP1257270B1 (en) * | 2000-02-15 | 2005-04-13 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| DK1381356T3 (da) | 2001-04-05 | 2008-09-22 | Aventis Pharma Inc | Anvendelse af (z)-z-cyano-3-hydroxy-but-2-enoinsyre-(4-trifluoromethylphenyl) - amide til behandling af multipel sclerose |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| BRPI0416752B8 (pt) | 2003-11-21 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composição farmacêutica, uso de um ou mais compostos, e, compostos |
| SG142305A1 (en) * | 2004-10-19 | 2008-05-28 | Aventis Pharma Inc | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'- trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| DK2094676T3 (da) | 2006-11-23 | 2013-06-10 | Actelion Pharmaceuticals Ltd | Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| CA2716448A1 (en) | 2008-03-17 | 2009-09-24 | Patrick Brossard | Dosing regimen for a selective s1p1 receptor agonist |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| CA2772275A1 (en) | 2009-09-18 | 2011-03-24 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| JP2013533286A (ja) | 2010-07-30 | 2013-08-22 | セントルイス ユニバーシティ | 疼痛を治療する方法 |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| HUE050733T2 (hu) | 2012-08-17 | 2021-01-28 | Actelion Pharmaceuticals Ltd | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék |
| WO2016079687A1 (en) | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| HUE057865T2 (hu) | 2014-12-11 | 2022-06-28 | Actelion Pharmaceuticals Ltd | A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| JP2018517736A (ja) | 2015-06-18 | 2018-07-05 | マティナス バイオファーマ ナノテクノロジーズ，インコーポレーテッド | 炎症性疾患又は病態を治療する組成物及び方法 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/en not_active Ceased
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 CA CA3056301A patent/CA3056301C/en active Active
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/en active Pending
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US12527772B2/en active Active
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
-
2025
- 2025-12-22 US US19/429,084 patent/US20260108501A1/en active Pending